Core Viewpoint - The stock of HeFu China reached a limit-up on December 2, closing at 25.56 yuan per share, with a total market capitalization of 10.174 billion yuan, driven by policy support and business developments [1] Group 1: Stock Performance - HeFu China closed at 25.56 yuan per share on December 2, with a trading volume of 2.478 billion yuan and a market cap of 10.174 billion yuan [1] - The stock has experienced 14 limit-ups over the past 23 trading days [1] Group 2: Factors Influencing Stock Movement - Policy factors include the release of the fifth batch of measures by the Fujian government to promote cross-strait integration, addressing the needs of Taiwanese individuals and enterprises [1] - The company's business is related to the sales and supply chain management of in vitro diagnostic products, covering over 3,700 items from more than 1,000 manufacturers, providing customized cost-reduction solutions for medical institutions [1] - HeFu China has developed a digital management software called "ZhiBeiTa" for hospital department operation management, facilitating cross-strait medical resource exchange [1] Group 3: Financial Performance - For the period from January to September 2025, HeFu China reported operating revenue of 549 million yuan, a year-on-year decrease of 22.80% [1] - The net profit attributable to the parent company was -12.3862 million yuan, representing a year-on-year decrease of 146.65% [1]